REGN
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc historical holders
total: 8
Dodge & Cox Stock Fund Regeneron Pharmaceuticals Inc transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Added:
- 8
- Reduced:
- 2
- Held since:
- 2021 Q4
- Held for:
- 18 quarters
- Latest activity:
- 2026 Q1
Dodge & Cox Stock Fund has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2021 Q4. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 2,908,804 shares with a market value of roughly $2.25B representing 1.96% of their equity portfolio. The fund/company first acquired REGN in 2021 Q4, initially purchasing 108,609 shares. Since the initial investment, Dodge & Cox Stock Fund has made 10 more transactions in this position.
Does Dodge & Cox Stock Fund still hold REGN?
Yes, Dodge & Cox Stock Fund continues to hold Regeneron Pharmaceuticals Inc (REGN). According to their 2026 Q1 report, they maintain a position of 2,908,804 shares valued at approximately $2.25B, representing 1.96% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in REGN?
Dodge & Cox Stock Fund first invested in Regeneron Pharmaceuticals Inc (REGN) in 2021 Q4 at the reported quarter-end price of $631.52 per share, acquiring 108,609 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for REGN?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $629.59 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $629.59
- Weighted AVG sell price:
- $771.60
REGN transactions history by Dodge & Cox Stock Fund
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
1.96%
|
2,908,804
|
$772.64
|
$2,247,458,323
|
-2.87% (-85,900)
|
-0.06%
|
|
2025 Q4
|
1.93%
|
2,994,704
|
$771.87
|
$2,311,522,176
|
+2.46% (+71,824)
|
+0.05%
|
|
2025 Q3
|
1.37%
|
2,922,880
|
$562.27
|
$1,643,447,738
|
+20.33% (+493,895)
|
+0.23%
|
|
2025 Q2
|
1.09%
|
2,428,985
|
$525.00
|
$1,275,217,125
|
+56.33% (+875,200)
|
+0.39%
|
|
2024 Q4
|
0.99%
|
1,553,785
|
$712.33
|
$1,106,807,669
|
-0.10% (-1,500)
|
-0%
|
|
2023 Q3
|
1.38%
|
1,555,285
|
$822.96
|
$1,279,937,344
|
+0.47% (+7,200)
|
+0.01%
|
|
2023 Q2
|
1.20%
|
1,548,085
|
$718.54
|
$1,112,360,996
|
+0.36% (+5,600)
|
+0%
|
|
2023 Q1
|
1.43%
|
1,542,485
|
$821.67
|
$1,267,413,650
|
+8.30% (+118,200)
|
+0.11%
|
|
2022 Q3
|
1.24%
|
1,424,285
|
$688.87
|
$981,147,208
|
+6.17% (+82,800)
|
+0.07%
|
|
2022 Q1
|
0.95%
|
1,341,485
|
$698.42
|
$936,919,954
|
+1,135.15% (+1,232,876)
|
+0.87%
|
|
2021 Q4
|
0.07%
|
$631.52
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.